694 related articles for article (PubMed ID: 33476650)
1. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
2. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
3. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
6. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
[TBL] [Abstract][Full Text] [Related]
7. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
[TBL] [Abstract][Full Text] [Related]
9. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
12. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
15. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
17. A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept.
Mahasa KJ; Ouifki R; Eladdadi A; Pillis L
Math Biosci Eng; 2022 Mar; 19(5):4429-4457. PubMed ID: 35430822
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
19. Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.
Ajina A; Maher J
Prog Mol Biol Transl Sci; 2019; 164():217-292. PubMed ID: 31383406
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Evgin L; Kottke T; Tonne J; Thompson J; Huff AL; van Vloten J; Moore M; Michael J; Driscoll C; Pulido J; Swanson E; Kennedy R; Coffey M; Loghmani H; Sanchez-Perez L; Olivier G; Harrington K; Pandha H; Melcher A; Diaz RM; Vile RG
Sci Transl Med; 2022 Apr; 14(640):eabn2231. PubMed ID: 35417192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
